Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmacia To Publish Full 12-Month Data From CLASS Study Of Celebrex

Executive Summary

Pharmacia is preparing to publish the full 12-month data from the Celebrex CLASS GI outcomes study.
Advertisement

Related Content

Conflict of Interest Policy Limits Industry Control Over Studies, Publication
Conflict of Interest Policy Limits Industry Control Over Studies, Publication
Journals' conflict of interest policy
Journals' conflict of interest policy
FDA Anti-Inflammatory Division Director Will Be Celebrex Investigator Simon
FDA Anti-Inflammatory Division Director Will Be Celebrex Investigator Simon
FDA Chief Counsel Is Attorney From WLF Case; Porter Leaves After 11 Years
COX-2 Class Labeling From Vioxx/Celebrex Data Proposed By FDA Consultant
COX-2 Class Labeling From Vioxx/Celebrex Data Proposed By FDA Consultant
Searle To Discuss Adding Celebrex 13-Month Safety Data To Label With FDA
Advertisement
UsernamePublicRestriction

Register

PS038375

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel